IRON DEFICIENCY ANEMIA TREATMENT MARKET Size and trends

Iron Deficiency Anemia Treatment Market Size and Trends

Global iron deficiency anemia treatment market is estimated to be valued at US$ 13.17 Bn in 2025 and is expected to reach US$ 23.78 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 8.8% from 2025 to 2032.

To learn more about this report, Request sample copy

Global iron deficiency anemia treatment market has significant growth potential over the forecast period  due to high prevalence of iron deficiency anemia worldwide, especially among pregnant women and children under five years of age in developing regions. The market growth will be driven by increasing healthcare expenditures and rising awareness about iron deficiency anemia screening and management. However, the market may face restraints from the availability of alternative medical therapies and dietary supplements. North America and Europe will continue to dominate the iron deficiency anemia treatment market, owing to rising incidence of IDA among elderly populations. However, Asia Pacific is expected to witness the fastest growth owing to high population density, growing geriatric demographic, and rising health consciousness. The market will witness numerous opportunities arising from new product launches, increasing healthcare access in emerging countries, and the growth of medical tourism in Asia.

Increasing Product Launches/Approval

Increasing adoption of inorganic growth strategies such as product launches approvals is expected to drive the market growth over the forecast period. For instance, in January 2021, Pharmascience Inc., a pharmaceutical company, announced the launch of pms-IRON SUCROSE, a generic drug with demonstrated bioequivalence to the brand name VENOFER for the treatment of iron deficiency anemia in patients with chronic kidney disease.